MASUI Sho

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy Division of Integrative Clinical Pharmacology ( Shiba-Kyoritsu )

Position

Research Associate/Assistant Professor/Instructor

Related Websites
Scopus Paper Info  
Paper Count: 9 Citation Count: 41 h-index: 4

Click to view the Scopus page. The data was downloaded from Scopus API in October 18, 2026, via http://api.elsevier.com and http://www.scopus.com .

Page Top ▲

Academic Degrees 【 Display / hide 】

  • 博士（薬学）, Kyoto University, Coursework, 2023.03

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • 薬剤師, 2019.04

Page Top ▲
 

Papers 【 Display / hide 】

  • Population pharmacokinetic analysis of bevacizumab in Japanese cancer patients with proteinuria: a prospective cohort study

    Masuda, T; Funakoshi, T; Horimatsu, T; Masui, S; Hira, D; Inoue, M; Yajima, K; Nakagawa, S; Ikemi, Y; Hamanishi, J; Takai, A; Yamamoto, S; Matsubara, T; Mandai, M; Seno, H; Yanagita, M; Muto, M; Terada, T; Yonezawa, A

    CANCER CHEMOTHERAPY AND PHARMACOLOGY 95 ( 1 )  2025.12

    ISSN  0344-5704

  • Low serum concentrations of bevacizumab and nivolumab owing to excessive urinary loss in patients with proteinuria: a case series.

    Masuda T, Funakoshi T, Horimatsu T, Yamamoto S, Matsubara T, Masui S, Nakagawa S, Ikemi Y, Yanagita M, Muto M, Terada T, Yonezawa A

    Cancer chemotherapy and pharmacology 94 ( 4 ) 615 - 622 2024.03

    ISSN  0344-5704

  • Comparison of safety and effectiveness between etanercept biosimilar LBEC0101 and reference in patients with rheumatoid arthritis in real-world data using the KURAMA cohort.

    Kawakami T, Masui S, Onishi A, Onizawa H, Fujii T, Murakami K, Murata K, Tanaka M, Shimada T, Nakagawa S, Matsuda S, Morinobu A, Terada T, Yonezawa A

    Modern rheumatology 34 ( 6 ) 1135 - 1141 2024.03

    ISSN  1439-7595

  • Clinical characteristics of cryopyrin-associated periodic syndrome and long-term real-world efficacy and tolerability of canakinumab in Japan: results of a nationwide survey

    Takayuki Miyamoto, Kazushi Izawa, Sho Masui, Atsue Yamazaki, Yuichi Yamasaki, Tadashi Matsubayashi, Mayuka Shiraki, Hidenori Ohnishi, Junko Yasumura, Kawabe Tomohiro, Takako Miyamae, Tomoyo Matsubara, Naoya Arakawa, Takashi Ishige, Takumi Takizawa, Asami Shimbo, Masaki Shimizu, Naoki Kimura, Yuichi Maeda, Yuta Maruyama, Tomonari Shigemura, Junichi Furuta, Satoshi Sato, Hiroshi Tanaka, Miharu Izumikawa, Masahiro Yamamura, Toshio Hasegawa, Hiroshi Kaneko, Yasuo Nakagishi, Naoko Nakano, Yasunori Iida, Tamaki Nakamura, Hiroyuki Wakiguchi, Takayuki Hoshina, Toshinao Kawai, Kosaku Murakami, Shuji Akizuki, Akio Morinobu, Koichiro Ohmura, Katsuhide Eguchi, Motoshi Sonoda, Masataka Ishimura, Kenji Furuno, Momoko Kashiwado, Masaaki Mori, Kimito Kawahata, Koremasa Hayama, Kumiko Shimoyama, Natsuko Sasaki, Taisuke Ito, Hiroaki Umebayashi, Tae Omori, Seiko Nakamichi, Tomotsune Dohmoto, Yasuyuki Hasegawa, Hisashi Kawashima, Shojiro Watanabe, Yuichiro Taguchi, Haruna Nakaseko, Naomi Iwata, Hiroki Kohno, Taiki Ando, Yasuhiko Ito, Yuko Kataoka, Takako Saeki, Utako Kaneko, Ayako Murase, Seira Hattori, Tomo Nozawa, Kenichi Nishimura, Reiji Nakano, Misa Watanabe, Masato Yashiro, Tomonori Nakamura, Toshihiko Komai, Kentaro Kato, Yoshitaka Honda, Eitaro Hiejima, Atsushi Yonezawa, Kazuhisa Bessho, Satoshi Okada, Osamu Ohara, Junko Takita, Takahiro Yasumi, Ryuta Nishikomori; Japan CAPS working group

    Arthritis Rheumatol  2024.01

    Research paper (scientific journal), Joint Work, Accepted

  • Serum Concentrations of Infliximab and IL-6 for Predicting One-Year Discontinuation of Infliximab Treatment Owing to Secondary Non-response in Patients with Rheumatoid Arthritis.

    Masui S, Yonezawa A, Nakamura M, Onishi A, Hashimoto M, Onizawa H, Fujii T, Murakami K, Murata K, Tanaka M, Yokoyama K, Iwamoto N, Shimada T, Itohara K, Hira D, Nakagawa S, Imai S, Nakagawa T, Hayakari M, Matsuda S, Morinobu A, Terada T, Matsubara K

    Biological & pharmaceutical bulletin (Biological and Pharmaceutical Bulletin)  46 ( 8 ) 1112 - 1119 2023

    Research paper (scientific journal), Joint Work, Lead author, Accepted,  ISSN  0918-6158

    　View Summary

    Secondary non-response to infliximab (IFX) occurs in some patients with rheumatoid arthritis (RA). Although therapeutic drug monitoring (TDM) is a useful tool to optimize IFX therapy, it is unclear whether it can help to identify the risk of secondary non-response. This study aimed to explore the utility of serum levels of IFX or other biomarkers to predict IFX discontinuation owing to secondary non-response. A single-center, retrospective study was conducted using the Kyoto University Rheumatoid Arthritis Management Alliance cohort database between 2011 and 2020. Serum IFX levels were measured using liquid chromatography-tandem mass spectrometry. An electrochemiluminescence assay was used to quantify serum levels of tumor necrosis factor-α and interleukin-6 and detect anti-drug antibodies. Eighty-four out of 310 patients were eligible for this study. The cutoff levels of biomarkers were determined by receiver operating characteristic analysis. IFX persistence was similar between groups stratified using IFX levels, tumor necrosis factor-α levels, interleukin-6 levels, and anti-drug antibodies positivity. The group with lower IFX and higher interleukin-6 levels had the worst therapy persistence (p=0.017) and the most frequent disease worsening (90.0%, p<0.001). Evaluating both interleukin-6 and IFX levels, not just IFX alone, enabled us to identify patients at risk of discontinuing IFX treatment. These findings support the utility of measuring IFX and interleukin-6 levels for successful maintenance therapy for RA.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

Page Top ▲

Presentations 【 Display / hide 】

  • ブレンツキシマブベドチンにおける薬物結合ペプチドの分析手法確立

    髙取 実咲, 高橋 信, 増井 翔, 矢島 広大, 嶋田 崇史, 米澤 淳

    [Domestic presentation]  第9回フレッシャーズ・カンファランス, 

    2026.07
    , 

    Oral presentation (general)

  • インフリキシマブ治療中の炎症性腸疾患患者における抗薬物抗体発生の実態調査

    大岩由佳，岩船杏南，矢島広大，増井翔，嶋田崇史，岡部誠，寺田智祐，米澤淳

    [Domestic presentation]  第42回日本TDM学会・学術大会, 

    2026.07
    , 

    Oral presentation (general)

  • 炎症性腸疾患モデルマウスにおける腸組織中インフリキシマブおよびTNF-α濃度の定量的評価

    石脇 佳純, 矢島 広大, 外西 美帆, 長縄 華子,増井 翔, 今吉 菜月, 嶋田 崇史, 津田 真弘, 寺田 智祐, 米澤 淳

    [Domestic presentation]  第9回フレッシャーズ・カンファランス, 

    2026.07
    , 

    Oral presentation (general)

  • 構造改変薬物を用いた抗エタネルセプト抗体のエピトープ探索

    岩井 華那, 岡本 恵理子, 矢島 広大, 中山 葵, 増井 翔, 大西 輝, 寺田 智祐, 米澤 淳

    [Domestic presentation]  医療薬学フォーラム2026 第34回クリニカルファーマシーシンポジウム, 

    2026.06
    , 

    Poster presentation

  • 抗体医薬品の添付文書における抗薬物抗体関連情報の記述的分析

    矢島広大, 佐藤輝, 増井翔, 柴田寛子, 西村和子, 石井明子, 米澤淳

    [Domestic presentation]  日本薬学会第146年会, 

    2026.03
    , 

    Oral presentation (general)

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • Exploring the effect of Biotransformation on the Infliximab PK/PD profile

    2024.04
    -
    2027.03

    若手研究, Principal investigator

Page Top ▲

Awards 【 Display / hide 】

  • International Session Award

    2025.11, 第35回日本医療薬学会年会, Evaluation of infliximab biotransformation through comparison of quantification by ligand-binding assay and mass spectrometry

    Type of Award： Award from Japanese society, conference, symposium, etc.

  • 2024年度 Postdoctoral Award

    2024.06, 一般社団法人 日本医療薬学会, リアルワールドデータ解析に基づく抗TNF-α抗体医薬品の適正使用に関する研究

    Type of Award： Award from Japanese society, conference, symposium, etc.

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • PRE-CLINICAL TRAINING FOR HOSPITAL & COMMUNITY PHARMACY

    2026

  • SEMINAR(INTEGRATIVE CLINICAL PHARMACOLOGY)

    2026

  • STUDY OF MAJOR FIELD(INTEGRATIVE CLINICAL PHARMACOLOGY)

    2026

  • BIOTECH-DISCOVERY-BASED MEDICINE AND GENOME INFORMATICS

    2026

  • PHARMACEUTICAL-ENGLISH SEMINAR

    2026

display all >>

Page Top ▲
 

Memberships in Academic Societies 【 Display / hide 】

  • 日本臨床薬理学会, 

    2025.05
    -
    Present

  • 日本抗体学会, 

    2022.10
    -
    Present

  • 日本臨床疫学会, 

    2019.09
    -
    Present

  • 日本薬学会, 

    2018.09
    -
    Present

  • 日本医療薬学会, 

    2017.06
    -
    Present
Page Top ▲

Committee Experiences 【 Display / hide 】

  • 2024.11
    -
    2025.11

    第35回日本医療薬学会年会　実行委員

Page Top ▲